Pfizer
Most Read
Belgian pharma UCB to buy Zogenix, maker of rare epilepsy treatment, for $1.9 billion
It’s all in the details: start-up packages and ongoing gender bias in academic medicine
Pharmacies shouldn’t be the only place to get Paxlovid, the new Covid pill
What types of mental health apps actually work? A sweeping new analysis takes stock of the evidence
After Omicron, we could use a break. We may just get it
With $3 billion, Hal Barron and other biotech veterans launch a disease ‘reversal’ company
Patent thickets are thwarting U.S. availability of lower-cost biosimilar medicines, study finds
All Coverage
advertisement
